한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제31권2호
  • /
  • Pages.77-84
  • /
  • 2014
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지

개에서 재조합 과립구 자극 인자 (rh G-CSF)의 투여 간격에 따른 말초혈액과 골수의 반응에 대한 연구

A Study of Peripheral Blood and Bone Marrow Responses Depends on the Frequency of rhG-CSF Administration in Dogs

  • 김지현 (경상대학교 수의과대학 동물의학연구소) ;
  • 지초희 (경상대학교 수의과대학 동물의학연구소) ;
  • 원진희 (경상대학교 수의과대학 동물의학연구소) ;
  • 정해원 (경상대학교 수의과대학 동물의학연구소) ;
  • 문종현 (경상대학교 수의과대학 동물의학연구소) ;
  • 조규완 (경상대학교 수의과대학 동물의학연구소) ;
  • 강병택 (충북대학교 수의과대학) ;
  • 정동인 (경상대학교 수의과대학 동물의학연구소)
  • Kim, Ji-Hyun (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Jee, Cho-Hee (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Won, Jin-Hee (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Jung, Hae-Won (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Moon, Jong-Hyun (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Cho, Kyu-Woan (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Kang, Byeong-Teck (Laboratory of Veterinary Dermatology and Neurology, College of Veterinary Medicine, Chungbuk National University) ;
  • Jung, Dong-In (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
  • 심사 : 2014.04.14
  • 발행 : 2014.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

본 연구는 사람 재조합과립구자극인자 (rhG-CSF) 투여 간격에 따른 말초혈액과 골수의 변화를 평가하였다. 사람 재조합과립구자극인자는 개에서 항암치료 후 나타나는 골수억압 등에서 유용한 치료효과가 있는 것으로 알려져 있으나 그 투여간격에 따른 연구는 아직 진행되지 않았다. 따라서 본 연구에서는 다음과 같은 간격으로 실험 기간 동안 각각 2마리씩 3그룹으로 체중당 $5{\mu}g$으로 사람 재조합과립구자극인자를 주사하였다; (1) 하루에 한번 주사; 그룹 1, (2) 2일에 한번 주사; 그룹 2, (3) 3일에 한번 주사; 그룹 3, 말초혈액 분석과 100개의 직접 현미경 세포계수는 매일 실시하였다. 골수천자는 0일차, 3일차 9일차 마지막으로 말초혈액상 총 백혈구수가 정상범위내로 떨어지는 12일차 혹은 13일차에 시행하였다. 사람 재조합과립구자극인자는 모든 실험견에서 잘 투여되었으며 부작용을 보이지 않았다. 이러한 본 연구의 결과에 따르면 체중당 $5{\mu}g$의 사람 재조합과립구자극인자의 투여는 말초혈액과 골수에서 세포특이적이고 투여간격에 대체적으로 비례하는 효과를 보였으며 사람 재조합과립구자극인자 투여가 반복될수록 그 효과는 증가하였으며 사람 재조합과립구자극인자 투여를 중지한 이후에도 골수에 미치는 효과는 3일이상 지속되는 것으로 보여졌다. 따라서 본 연구의 결과를 통해 임상가들은 적절한 치료 간격을 세울 수 있을 것으로 기대된다.

The present study evaluated that responses of peripheral and bone marrow depends on the frequency of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in dogs. The rhG-CSF has been revealed that have a beneficial effect for dogs with myelosuppression secondary to chemotherapy or radiation but there were no studies about the frequency of administration in dogs. In this research, rhG-CSF was administrated $5{\mu}g/kg$ subcutaneously for each two-dogs group as follows: (1) every day for trial, (2) every other day for trial, (3) every third day for trial. The peripheral blood analysis including direct microscopic differential counts of one hundred cells was performed every day. Bone marrow aspiration was performed before administration of rh G-CSF, on the day of 0, 3, 9 and when the WBC counts were decreased within the normal range (day 12 or 13). Rh G-CSF was well-tolerated and showed no side effects in all dogs. According to the present study, $5{\mu}g/kg$ administration of rhG-CSF have cell-specific, frequency-related effect on bone marrow and peripheral blood. Furthermore, the effects of rhG-CSF administration on bone marrow sustained during the study and prolonged at least 3 days after discontinuing of rhG-CSF treatment.

키워드

참고문헌

  1. Carulli G. Effects of recombinant human granulocyte colonystimulating factor administration on neutrophil phenotype and functions. Haematologica 1997; 82: 606-616.
  2. Clark SC, Kamen R. The human hematopoietic colonystimulating factors. Science 1987; 236: 1229-1237. https://doi.org/10.1126/science.3296190
  3. Couto CG. Leukopenia and leukocytosis. In: Small animal internal medicine. 4th ed. St. Louis: Elsvier Mosby. 2009: 1228-1235.
  4. Cullor JS, Smith W, Fairley N, Wood SL, Dellinger JD, Souza L. Effect of human granulocyte colony stimulating factor (HR-GCSF) on the hemogram of lactating dairy cattle. Vet Clin Pathol 1990; 19: 9-12. https://doi.org/10.1111/j.1939-165X.1990.tb00534.x
  5. Cullor JS, Fairley N, Smith WL, Wood SL, Dellinger JD, Inokuma MS, Souza LM. Hemogram changes in lactating dairy cows given human recombinant granulocyte colony stimulating factor. Vet Pathol 1990; 27: 311-316. https://doi.org/10.1177/030098589002700502
  6. Gabrilove JL, Jakubowski A. Granulocyte colony-stimulating factor: preclinical and clinical studies. Hematol Oncol Clin North Am 1989; 3: 427-440.
  7. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989; 321: 1449-1459. https://doi.org/10.1056/NEJM198911233212106
  8. Hammond WP, Csiba E, Canin A, Hockman H, Souza LM, Layton JE, Dale DC. Chronic neutropenia. A new canine model induced by human granulocyte colony-stimulating factor. J Clin Invest 1991; 87: 704-710. https://doi.org/10.1172/JCI115049
  9. Hasegawa T, Inomata T. Effect of recombinant human granulocyte colony stimulating factor on lymphocyte blastogenesis in healthy dogs. J Vet Med Sci 2000; 62: 1205-1207. https://doi.org/10.1292/jvms.62.1205
  10. Henry CJ, Buss MS, Lothrop CD. Veterinary uses of recombinant human granulocyte colony-stimulating factor. I. Oncology. Compend Contin Educ Prac Vet 1998; 20: 728-735.
  11. Ikebuchi K, Clark SC, Ihle JN, Souza LM, Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A 1988; 85: 3445-3449. https://doi.org/10.1073/pnas.85.10.3445
  12. Jakubowski AA, Souza L, Kelly F, Fain K, Budman D, Clarkson B, Bonilla MA, Moore MA, Gabrilove J. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 1989; 320: 38-42. https://doi.org/10.1056/NEJM198901053200107
  13. Karawajczyk M, Höglund M, Ericsson J, Venge P. Administration of G-CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteins. Br J Haematol 1997; 96: 259-265. https://doi.org/10.1046/j.1365-2141.1997.d01-2045.x
  14. Kerst JM, De Haas M, Van Der Schoot C E, Slaper- Cortenbach ICM, Kleijer M, Von Dem Borne AEGKR, Van Oers RHJ. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers : Induction of immunophenotypically and functionally altered neutrophils via an effects on myeloid progenitor cells. Blood 1993; 82: 3265-3272.
  15. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. New Engl J Med 1992; 327: 28-35. https://doi.org/10.1056/NEJM199207023270106
  16. Lindemann A, Herrmann F, Oster W, Haffner G, Souza L, Mertelsmann R. Hematologic effects of recombinant granulocyte colony-stimulating factor in patients with malignancies. Blood 1989; 74: 2644-2651.
  17. Lothrop CD Jr., Warren DJ, Souza LM, Jones JB, Moore MA. Correction of canine cyclic hematopoiesis with recombinant human granulocyte colony-stimulating factor. Blood 1988; 72: 1324-1328.
  18. MacVittie TJ, Monroy RL, Patchen ML, Souza LM. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. Int J Radiat Biol 1990; 57: 723-736. https://doi.org/10.1080/09553009014550891
  19. Mayer P, Werner FJ, Lam C, Besemer J. In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs. Exp Hematol 1990; 18: 1026-1033.
  20. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1993; 7: 67-83.
  21. Mischke R, Barth T, Wohlsein P, Rohn K, Nolte I. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci 2001; 70: 221-225. https://doi.org/10.1053/rvsc.2001.0464
  22. Mishu L, Callahan G, Allebban Z, Maddux JM, Boone TC, Souza LM, Lothrop CD Jr. Effects of recombinant canine granulocyte colony-stimulating factor on white blood cell production in clinically normal and neutropenic dogs. J Am Vet Med Assoc 1992; 200: 1957-1964.
  23. Morstyn G, Foote M, Lieschke GJ. Hematopoietic growth factors in cancer chemotherapy. Cancer Chemother Biol Response Modif 1996; 16: 295-314.
  24. Obradovich JE, Ogilvie GK, Powers BE, Boone T. Evaluation of recombinant canine granulocyte colony-stimulating factor as an inducer of granulopoiesis. A pilot study. J Vet Intern Med 1991; 5: 75-79. https://doi.org/10.1111/j.1939-1676.1991.tb00935.x
  25. Ogilvie GK, Obradovich JE. Hematopoitic growth factors: clinical use and implications. In: Kirk's current veterinary therapy, 6th ed. London: WB Saunders Co. 1992: 466-470.
  26. Rewerts JM, McCaw DL, Cohn LA, Wagner-Mann C, Harrington D. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 1998; 213: 991-992.
  27. Robinson BE, Quesenberry PJ. Hematopoietic growth factors: overview and clinical applications, Part III. Am J Med Sci 1990; 300: 311-321. https://doi.org/10.1097/00000441-199011000-00008
  28. Ruef C, Coleman DL. Granulocyte-macrophage colonystimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990; 12: 41-62. https://doi.org/10.1093/clinids/12.1.41
  29. Schuening FG, Storb R, Goehle S, Graham TC, Appelbaum FR, Hackman R, Souza LM. 1989. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1989; 74: 1308-1313.
  30. Sieff CA. Hematopoietic growth factors. Clin Invest 1987; 79: 1549-1957. https://doi.org/10.1172/JCI112988
  31. Stabel JR, Kehrli ME Jr, Thurston JR, Goff JP, Boone TC. Granulocyte colony-stimulating factor effects on lymphocytes and immunoglobulin concentrations in periparturient cows. J Dairy Sci 1991; 74: 3755-3762. https://doi.org/10.3168/jds.S0022-0302(91)78567-6
  32. Tegg EM, Tuck DM, Lowenthal RM, Marsden KA. The effect of G-CSF on the composition of human bone marrow. Clin Lab Haematol 1999; 21: 265-270. https://doi.org/10.1046/j.1365-2257.1999.00227.x
  33. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU. Effects of recombinant human granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545. https://doi.org/10.1056/NEJM198712173172501
  34. Weaver CH, Longin K, Buckner CD, Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 13: 411-415.
  35. Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore MA, O'Reilly RJ, Souza LM. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165: 941-948. https://doi.org/10.1084/jem.165.4.941
  36. Yakushijin Y, Shikata H, Takaoka I, Horikawa T, Takeuchi K, Yamanouchi J, Azuma T, Narumi H, Hato T, Yasukawa M. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy. Int J Clin Oncol 2011; 16: 118-124. https://doi.org/10.1007/s10147-010-0134-x
  37. Zinkl JG, Cain G, Jain NC, Sousa LM. Haematologic response of dogs to canine recombinant granulocyte colony stimulating factor (rcG-CSF). Comp Hematol Int 1992; 2: 151-156. https://doi.org/10.1007/BF00426169
  38. Zsebo KM, Cohen AM, Murdock DC, Boone TC, Inoue H, Chazin VR, Hines D, Souza LM. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 1986; 172: 175-184. https://doi.org/10.1016/S0171-2985(86)80097-3